Streamex (STEX) AI Stock Analysis

• Market Cap: $219.03M
• Dividend Yield: N/A
• Average Volume (3M): 994.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: -67.50%
• EPS Growth: 45.54%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Asset Management
• EPS (TTM): N/A
• Shares Outstanding: 35,270,943
• 10 Day Avg. Volume: 1,305,368
• 30 Day Avg. Volume: 994,038
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.04
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

BioSig Technologies faces significant financial difficulties, with persistent losses, high leverage, and negative cash flow trends. While technical analysis indicates some short-term momentum, potential overbought conditions warrant caution. The negative P/E ratio further underscores valuation challenges and risks associated with the stock.

Streamex Business Overview & Revenue Model

Company Description

BioSig Technologies, Inc. is a medical technology company that operates in the healthcare sector, focusing on advanced signal processing solutions for the medical industry. The company's core product is the PURE EP System, an innovative platform designed to improve the clarity and precision of cardiac signal data during electrophysiology (EP) procedures. This technology aims to enhance the diagnosis and treatment of complex arrhythmias by providing physicians with clearer, more interpretable data, potentially improving patient outcomes.

How the Company Makes Money

BioSig Technologies generates revenue primarily through the sale and lease of its PURE EP System to hospitals and medical institutions. The company also earns money by providing ongoing support services, including maintenance and upgrades, to ensure optimal performance of its systems. Additionally, BioSig may enter into strategic partnerships and collaborations with other healthcare entities and technology providers to expand its market reach and enhance its technological offerings. Key revenue streams include direct sales, leasing agreements, and service contracts associated with the PURE EP System.

Streamex Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Streamex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STEX, the sentiment is Positive. The current price of 6.4 is above the 20-day moving average (MA) of 5.16, above the 50-day MA of 4.94, and above the 200-day MA of 3.03, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 63.05 is Neutral, neither overbought nor oversold. The STOCH value of 84.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STEX.

Streamex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VVOS	48 Neutral	26.42M	-1.78	-140.01%	―	2.65%	70.21%
CODX	45 Neutral	16.07M	-0.38	-69.30%	―	-91.14%	9.47%
ADGM	45 Neutral	25.07M	-0.37	-270.00%	―	15.00%	71.57%
PAVM	42 Neutral	8.73M	0.36	178.66%	―	-73.36%	0.00%
AXDXQ	37 Underperform	25.00	>-0.01	89.30%	―	-2.99%	59.87%
STEX	34 Underperform	$219.03M	―		―	-67.50%	45.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%